Summit Therapeutics PLC. Daily Stock Analysis

Daily Stock Analysis, SMMT, Summit Therapeutics PLC, priceseries

Summit Therapeutics PLC. Daily Stock Analysis
Stock Information
Open
2.78
Close
2.84
High
2.87
Low
2.73
Previous Close
2.76
Daily Price Gain
0.08
YTD High
3.42
YTD High Date
Mar 2, 2022
YTD Low
1.88
YTD Low Date
Jan 24, 2022
YTD Price Change
0.02
YTD Gain
0.71%
52 Week High
8.70
52 Week High Date
May 21, 2021
52 Week Low
1.88
52 Week Low Date
Jan 24, 2022
52 Week Price Change
-2.76
52 Week Gain
-49.29%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 13. 2017
11.39
Mar 9. 2017
12.43
17 Trading Days
9.16%
Link
LONG
Jul 24. 2017
12.60
Aug 9. 2017
13.73
12 Trading Days
8.98%
Link
LONG
Nov 17. 2017
10.69
Dec 6. 2017
11.37
12 Trading Days
6.30%
Link
LONG
Jan 8. 2018
11.19
Feb 2. 2018
13.07
18 Trading Days
16.82%
Link
LONG
Mar 2. 2018
12.28
Mar 19. 2018
12.98
11 Trading Days
5.73%
Link
LONG
Jan 3. 2019
1.34
Jan 15. 2019
1.48
8 Trading Days
10.44%
Link
LONG
Feb 26. 2019
1.87
Mar 8. 2019
2.04
8 Trading Days
9.17%
Link
LONG
Mar 10. 2020
1.70
Mar 23. 2020
2.17
9 Trading Days
27.51%
Link
LONG
Apr 7. 2020
2.38
Apr 23. 2020
3.69
11 Trading Days
55.20%
Link
LONG
May 20. 2020
3.55
Jun 1. 2020
3.73
7 Trading Days
5.17%
Link
LONG
Nov 10. 2020
3.38
Nov 24. 2020
4.14
10 Trading Days
22.53%
Link
LONG
Nov 27. 2020
4.34
Dec 28. 2020
5.46
20 Trading Days
25.91%
Link
LONG
Jan 21. 2021
5.35
Feb 10. 2021
8.29
14 Trading Days
54.91%
Link
LONG
May 17. 2021
6.85
Jun 8. 2021
7.55
15 Trading Days
10.19%
Link
Company Information
Stock Symbol
SMMT
Exchange
NasdaqGM
Company URL
http://www.summitplc.com
Company Phone
44-123-544-3939
CEO
Glyn O. Edwards
Headquarters
-
Business Address
136A EASTERN AVENUE, MILTON PARK, ABINGDON, UNITED KINGDOM OX14 4SB
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Other
CIK
0001599298
About

Summit Therapeutics Plc engages in the discovery, development and commercialization of novel medicines. It focuses on drug development business which covers the research and development activities carried out by the group, primarily comprising the Duchenne Muscular Dystrophy and the Clostridium Difficile Infection programs. The company was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, United Kingdom.

Description

Summit Corporation plc, a drug discovery and development company, engages in the discovery and development of novel drug candidates to treat areas of high unmet medical need. The company licenses its drug discovery platform, known as Seglin technology, for the identification of new drug leads and candidates with the potential to target a range of diseases. Its pipeline consists of clinical stage programmes targeting Duchenne Muscular Dystrophy (DMD) and Clostridium difficile infection (CDI). The company provides SMT C1100, a small molecule Utrophin modulator for DMD patients that has completed Phase I clinical trial; and SMT 19969, a Phase I clinical trial completed novel molecule antibiotic for the treatment for initial CDI and prevention of recurrent disease. It is also engaged in other programmes that include OGA inhibitor programme for the treatment of dementia. The company has a technology license agreement with Bristol-Myers Squibb to access the Seglin technology platform. It has operations primarily in the United Kingdom and the United States. The company was formerly known as VASTox plc and changed its name to Summit Corporation Plc in July 2007. Summit Corporation plc was founded in 2003 and is headquartered in Abingdon, the United Kingdom.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading